Alecensa (alectinib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Alecensa is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK)[3][4] and is used to treat non-small-cell lung cancer (NSCLC). It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.
Alecensa is used only if your cancer has a specific genetic marker (an abnormal “ALK” gene). Your doctor will test you for this gene.